Company intelligence / Profile preview
MODAG
- Ownership
- Private
- Development stage
- Other
Overview
MODAG has successfully completed a Phase 1 trial of its lead compound anle138b, demonstrating a favorable safety profile and plasma levels exceeding those required for efficacy in animal models. The company has initiated further clinical studies to evaluate safety and efficacy measures in patients with Parkinson's disease. Its approach aims to provide the first disease-modifying therapy for MSA by dissolving toxic intracellular oligomers implicated in neurodegeneration. The company also develops diagnostics to detect these pathological proteins early.
- Therapeutic areas
- Neurology
- Modalities
- small molecules
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on MODAG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MODAG.